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Background: Catheter ablation of hemodynamically unstable ventricular tachycardia (VT) is possible with
mechanical circulatory support (MCS), little is known regarding the relative safety and efﬁcacy of different
supporting devices for such procedures.
Methods and results: Sixteen consecutive patients (aged 63 ± 11 years with left ventricular ejection fraction
of 20 ± 9%) who underwent ablation of hemodynamically unstable VT were included in this study. Hemody-
namic support included percutaneous (Impella® 2.5, n = 5) and implantable left ventricular assist devices
(LVADs, n = 6) and peripheral cardiopulmonary bypass (CPB, n = 5). Except for 2 Impella cases, hemody-
namic support was adequate (with consistent mean arterial pressure of N60 mmHg) to permit sufﬁcient ac-
tivation mapping for ablation. In the Impella and CPB groups, mean time under hemodynamic support was
185 ± 86 min, and time in VT was 78 ± 36 min. Clinical VT could be terminated at least once by ablation
in all patients except 1 case with Impella due to hemodynamic instability. Peri-procedural complications in-
cluded hemolysis in 1 patient with Impella and surgical intervention for percutaneous Impella placement
problems in another 2. The median number of appropriately delivered deﬁbrillator therapies was signiﬁcant-
ly decreased from 6 in the month before VT ablation to 0 in the month following ablation (p = 0.001).
Conclusions: Our data suggest that peripheral CPB and implantable LVAD provide adequate hemodynamic
support for successful ablation of unstable VT. Impella® 2.5, on the other hand, was associated with increased
risk of complications, and may not provide sufﬁcient hemodynamic support in some cases.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Ventricular tachycardia (VT) is encountered in increasing numbers of
patients with advanced heart failure [1], and often causes frequent im-
plantable cardioverter deﬁbrillator (ICD) shocks [2,3].When amiodarone
and other pharmacological therapies fail, catheter ablation is usually the
only readily available treatment option for VT suppression in these pa-
tients. Unfortunately, many of these VTs are considered ineligible forry sinus; GFR, glomerular ﬁltra-
D, left ventricular assist device;
P, mean arterial pressure; MCS,
tion; VT, ventricular tachycardia.
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reland Ltd. Open access under CC BYconventional VTmapping and ablation, largely due to their hemodynam-
ic instability [2–10]. In these patients, mapping and ablation strategy
during sinus rhythm, such as pace-mapping or substrate-basedmapping
and ablation, may be attempted but usually with only moderate success
[5,11,12]. Initial case cohort reports have suggested that unstable VT
might be successfully ablatedwith the aid ofmechanical circulatory sup-
port (MCS) using a variety of devices [13–17]. Even with such support,
concerns remain regarding possible under-perfusion of vital organs dur-
ing unstable VT. At present, little is known regarding the relative efﬁcacy
of hemodynamic support by different MCS devices during such proce-
dures. This pilot study was designed to compare the hemodynamic sup-
port efﬁcacy of 3 different devices for catheter ablation of unstable VT
and to evaluate the acute and short-term outcomes of activation map-
ping and ablation strategy in these patients.2. Methods
This study was approved by the Institutional Review Board of the University of
Minnesota (study number 1110M05461). All data were collected from each patient
prospectively and kept carefully by the investigators.-NC-ND license.
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This study included 16 consecutive patients (between July 2010 and September
2012) who underwent catheter ablation of VT with MCS due to frequent refractory
VT episodes requiring multiple ICD therapies. Six of them had VT storms, deﬁned as
having ≥3 separate (N5 min) VT episodes requiring ICD therapies within 24 h; [18]
and 10 had 1.9 ± 1.1 previous ablation attempts.
The ﬁrst 5 consecutive patients underwent VT ablation under Impella support
(Impella group, Impella® 2.5, ABIOMED, Inc., Danvers, Massachusetts, USA) inserted
by interventional cardiologists. Additional 5 consecutive patients following the Impella
cohort had VT ablation supported with peripheral cardiopulmonary bypass (CPB
group, Performer®, Medtronic, Inc., Minneapolis, Minnesota, USA) inserted by cardio-
vascular surgeons. Each of these patients had at least 1 episode of hemodynamically
unstable VT, deﬁned as a mean arterial pressure (MAP) b45 mmHg without MCS
[16]. The control group included 6 consecutive patients with an implanted durable
continuous ﬂow left ventricular assist device (CF-LVAD group, HeartMate II, Thoratec,
Pleasanton, California, USA) who were referred for catheter ablation of VT during the
same time period.
2.2. Procedural details
The ablation procedure was performed under general anesthesia after written in-
formed consent was obtained. At the discretion of the anesthesiologists, bilateral cerebral
tissue regional oxygen saturation (rSO2) was monitored using near infrared spectroscopy
(INVOS™ 5100C Cerebral/Somatic Oximeter, Covidien,Mansﬁeld,Massachusetts, USA). In
peripheral CPB and CF-LVAD groups, an open-irrigation, 3.5 mm tip, deﬂectable catheter
(Thermocool, Biosense Webster, Diamond Bar, California, USA) was inserted via an 8.5 F
steerable sheath (Agilis, large curve, St. Jude Medical, St. Paul, Minnesota, USA) for map-
ping and ablation through a trans-septal approach or via an 8 F sheath employing a retro-
grade approach, or both (such double ablation catheter technique was used to minimize
the time in unstable VT by avoiding the time of exchanging ablation catheter placement
for easy access of some speciﬁc location of the left ventricle when needed). In the Impella
group, ablation catheterwas placed only through a trans-septal approach. The approaches
for catheter placement in the different groups were summarized in Table 1.
Systemic anticoagulation was achieved with intravenous heparin to maintain an
activated clotting time of 300–350 s for CF-LVADs and Impella, and 400–500 s for
CPB support. Fluid, phenylephrine, ephedrine, and/or dopamine were used as needed
to maintain MAP N60 mmHg [19]. If necessary, right and left atrial pressure was mea-
sured ﬁrst to optimize ﬂuid status and guide medical therapy in this study.
2.3. Cardiac assist devices
For the Impella group, the Preclose technique for arteriotomy site closure was used
(Perclose® ProGlide™, Abbott Laboratories, Abbott Park, Illinois, USA) with the assis-
tance of the interventional cardiology service [20,21]. For the CPB group, a 17 F arterial
cannula and a 25 F venous cannula were inserted using a small surgical cut down
approach.
2.4. Ablation strategy
Mapping and ablation were performed in all patients by one operator (FL). Activa-
tion mapping was performed using a 3-dimensional electroanatomical mapping sys-
tem: Carto system (Biosense Webster, Diamond Bar, California, USA) or EnSite NavX
system (St. Jude Medical, St. Paul, Minnesota, USA) [22]. For mapping VT circuits in
this study, activation mapping was primarily used with supplemental substrate map-
ping, pace mapping, and entrainment mapping. Ablation energy (usually 35–40 W
and up to 45–48 W as needed) was delivered to the targeted site for up to 120 s. If
VT was terminated with a radiofrequency lesion, additional ‘insurance’ burns were de-
livered to the surrounding area or to complete the linear ablation lesions suggested by
substrate mapping. If any subtle change in VT cycle length or QRS morphology with ab-
lation occurred, the VT was remapped and the alternative earliest site was sought forTable 1
Vascular access and catheter placement.
Group pCPB Impella CF-LVAD
Ablation via retrograde approach RFA N/A RFA
Ablation via trans-septal approach RFV RFV RFV
RVA catheter RFV⁎ RFV RFV
CS catheter RFV RFV RFV
ICE catheter RFV⁎ LFV LFV
MCS placement LFA + LFV LFA N/A
Note: CF-LVAD = continuous ﬂow left ventricular device; CS = coronary sinus; ICE =
intracardiac echocardiography; LFA = left femoral artery; LFV = left femoral vein;
MCS = mechanical circulatory support; N/A = not applicable; pCPB = peripheral
cardiopulmonary bypass; RFA = right femoral artery; RFV = right femoral vein;
RVA = right ventricular apex.
⁎ The right ventricular catheter and the intracardiac echocardiography catheter
shared the same access via the right femoral vein in pCPB group.ablation until successful termination of VT. No epicardial mapping and ablation were
needed in this study to achieve termination of clinically relevant VT.
Procedure time was deﬁned as the period from obtaining the ﬁrst vascular access
to the conclusion of the procedure; bypass time as the period from starting hemody-
namic support after set-up for MCS to termination of support after EP testing was com-
pleted; and VT time as the total duration of all episodes of monomorphic VT, lasting
10 s or more, during the course of the procedure [16].
The acute result of the ablation procedure was deﬁned as ‘successful’ if clinical VT
was non-inducible after its termination by ablation; and ‘possible successful’ when
clinical VT was terminated by ablation but still remained inducible at the end of the
procedure; and as ‘failed’ if the procedure did not meet either of the above criteria.
Clinical success was deﬁned as ≥75% reduction in the VT frequency over a 3 month
follow-up after ablation [3,23].
2.5. Renal function and lactate measurement
A basic metabolic panel, including creatinine, blood urea nitrogen, and glomerular
ﬁltration rate (GFR), was obtained before and the day after the procedure.When studied,
arterial and coronary sinus (CS) lactate levels weremeasured at baseline, during different
time periods in VT, and at the conclusion of the procedure in selected patients.
2.6. Statistical analysis
Continuous variables are expressed as mean ± standard deviation and were com-
pared using paired or unpaired Student t test, or one-way ANOVA as appropriate. The
number of VT episodes was expressed as median with range; and comparison of the
number of VT episodes before and after ablation was tested using paired Wilcoxon
signed rank test. Categorical variables were compared by chi-square analysis or with
Fisher exact test as appropriate. A 2-tailed p value b0.05 was considered statistically
signiﬁcant. SPSS version 19 was used for all data analysis in this study.
3. Results
Themean age of these 16 patientswas 63 ± 11 years. All had severe
cardiomyopathy with left ventricular end-diastolic dimension of 69 ±
12 mm, mean left ventricular ejection fraction (LVEF) of 20 ± 9%, and
New York Heart Association functional class of 3.22 ± 0.88. In patients
without CF-LVADs, their clinical VT cycle length was 359 ± 77 ms and
all had syncope or presyncope immediately prior to ICD shocks and 2
had shocks during sleeping. The clinical characteristics of these patients
are summarized in Table 2.
3.1. Procedure data
Hemodynamic and renal function measurements as well as proce-
dure data are summarized in Table 3. Procedure time was longer in
Impella group (394 ± 68 min) compared to CPB (307 ± 13 min,
p = 0.044) or CF-LVAD (310 ± 40 min, p = 0.049) groups. In the
CF-LVAD group, no signiﬁcant hemodynamic instability was noted dur-
ing VT with CF-LVAD support (MAP during VT was 78 ± 14 mmHg).
Since no VT time limit was set for mapping and ablation in these pa-
tients with CF-LVAD, the total time in VT tended to be longer in theTable 2
Patient clinical characteristics.
pCPB Impella CF-LVAD p Value
N 5 5 6
Sex (male/female) 5/0 5/0 5/1
Age (years) 61 ± 3 62 ± 15 65 ± 13 0.830
LVEF (%) 24 ± 11 23 ± 9 14 ± 6 0.138
LVESD (mm) 61 ± 16 55 ± 12 60 ± 16 0.755
LVEDD (mm) 71 ± 12 65 ± 9 70 ± 16 0.746
CAD 4 4 6 0.504
DCM 1 1 0 0.309
HTN 1 2 4 0.293
TCL (ms) 356 ± 103 363 ± 53 507 ± 21 0.003
Note: pCPB = peripheral cardiopulmonary bypass; DCM = idiopathic dilated
cardiomyopathy; HTN = hypertension; CF-LVAD = continuous ﬂow left ventricular
device; LVEF = left ventricular ejection fraction; LVEDD = left ventricular
end-diastolic dimension; LVESD = left ventricular end-systolic dimension; TCL =
clinical tachycardia cycle length.
Table 3
Ablation, hemodynamics, and renal function data.
pCPB Impella CF-LVAD p Value
VT cycle length (ms) 341 ± 89 440 ± 70 501 ± 88 0.023*
Procedure time (min) 307 ± 13 394 ± 68 310 ± 40 0.014*
Fluoroscopic time (min) 37 ± 8 45 ± 11 50 ± 23 0.483
No. of ablation lesions 36 ± 11 42 ± 10 43 ± 22 0.775
Total ablation time (min) 32 ± 8 24 ± 16 35 ± 17 0.828
Total time in VT (min) 83 ± 29 73 ± 45 145 ± 85 0.135
Total time on Support (min) 141 ± 15 240 ± 110 310 ± 40 0.002*
Baseline SBP (mmHg) 110 ± 11 113 ± 17 93 ± 16 0.089
SBP During VT (mmHg) 103 ± 6 92 ± 16 90 ± 25 0.442*
Baseline DBP (mmHg) 53 ± 12 65 ± 9 79 ± 11 0.007*
DBP During VT (mmHg) 68 ± 16 62 ± 13 72 ± 14 0.534
Baseline MBP (mmHg) 70 ± 13 79 ± 8 82 ± 11 0.201
MBP During VT (mmHg) 81 ± 10 73 ± 9 78 ± 14 0.540
Baseline HgB (g/dL) 11.9 ± 0.9 11.5 ± 2.1 10.4 ± 1.7 0.343
Post HgB (g/dL) 10.4 ± 0.15 10.4 ± 1.5 9.3 ± 1.9 0.473
Baseline Hct (%) 37 ± 3 34 ± 5 33 ± 5 0.337
Post Hct (%) 32 ± 5 32 ± 6 31 ± 4 0.907
Baseline GFR (mL/min/1.7 m2) 71 ± 14 71 ± 19 60 ± 12 0.452
Post GFR (mL/min/1.7 m2) 81 ± 6 67 ± 12 66 ± 11 0.292
Baseline Cr (μmol/L) 98 ± 19 97 ± 23 109 ± 15 0.526
Post Cr (μmol/L) 81 ± 14 115 ± 63 107 ± 16 0.354
Baseline BUN (mmol/L) 7.5 ± 5.4 7.1 ± 2.1 7.9 ± 4.6 0.942
Post BUN (mmol/L) 5.7 ± 2.9 6.1 ± 3.6 7.5 ± 3.9 0.725
Note: BUN = blood urea nitrogen; Cr = creatinine; DBP = diastolic blood pressure;
DCM = idiopathic dilated cardiomyopathy; GFR = glomerular ﬁltration rate; HgB =
hemoglobin; Hct = hematocrit; HTN = hypertension; CF-LVAD = continuous ﬂow
implantable left ventricular device; LVEF = left ventricular ejection fraction; MBP =
mean blood pressure; No. = number; pCPB = peripheral cardiopulmonary bypass;
Post = post procedure; SBP = systolic blood pressure; VT = ventricular tachycardia
(targeted for the ﬁrst ablation attempt).
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(Table 3).
WithoutMCS,MAP pressurewas b45 mmHgduring clinical VT in all
patients. When MAP was maintained N60 mmHg during MCS in the
absence of concerns about patient's other vital signs, hemodynamic
support was considered adequate (Table 3 and Fig. 1). This was the
case in all patients except for 2 patients supported with Impella. In pa-
tient A with Impella, MAP was maintained in the 60 s mmHg with ag-
gressive administration of vasopressor. We managed to complete theFig. 1. Arterial blood pressure recordings during ventricular tachycardia (VT) in 3 typical pat
support was considered adequate during VT when mean arterial pressure was maintained a
during Impella support compared with peripheral cardiopulmonary bypass (pCPB) and conablation procedure with intermittent interruption of his unstable VT.
In patient B with Impella, however, profound hypotension occurred
andprompted premature termination of theprocedurewithout ablation
attempt. Hemolysis was observed in 1 patient with Impella (patient C)
and failure to percutaneously insert Impella device due to difﬁcult access
in another (patient D). Surgical intervention was needed in 2 patients
with Impella due to bleeding (Patient B) and entangled Proclose device
(patient D), respectively. There was minimal blood loss after the proce-
dure compared with baseline (hemoglobin 10.0 ± 1.6 g/dl vs 11.2 ±
1.7 g/dl, p = 0.001; hematocrit 31.7 ± 4.0% vs 34.9 ± 4.6%, p =
0.003).
3.2. Acute ablation outcomes
The average cycle length of targeted clinical VT tended to be
shorter in CPB group compared to Impella group (341 ± 89 ms vs
440 ± 70 ms, p = 0.084). There were a total of 77 VTs induced in
the 16 patients, with a mean of 4.8 ± 1.9 (range 2–8) episodes per
patient. Clinical VT was terminated at least once in all patients
(Fig. 2). Acute success was achieved in 60%, 60%, and 50% in the
CPB, Impella, and CF-LVAD groups, respectively (p = 0.927). Clinical
relevant VT remained inducible in 7 of these 16 patients (44%) at
the end of the procedure.
3.3. Implantable LVAD function
There were no signiﬁcant peri-procedural complications associated
with CF-LVAD. The pump speed was not changed (median 8500 rpm)
and no signiﬁcant change was noted in pulsatility index (4.5 ± 0.4 vs
4.3 ± 0.3, p = 0.362) or power (5.5 ± 0.7 W vs 5.6 ± 0.8 W, p =
0.529) of CF-LVADs before and after ablation.
3.4. Cardiac response
Fig. 3(A) shows the lactate level drawn simultaneously from the
femoral artery and the CS in one patient under CPB support. Except
for slight elevation in both systemic and cardiac lactates during a
transient hypotension period (possibly due to sedation), lactate
remained stable over all the time during VT under CPB support.ients under different methods of mechanical circulatory support (MCS). Hemodynamic
bove 60 mmHg with MCS. Mean arterial pressure (MAP) during VT tended to be lower
tinuous ﬂow left ventricular assist device (CF-LVAD).
Fig. 2. Mapping and ablation of ventricular tachycardia (VT) in a patient under peripheral cardiopulmonary bypass (pCPB). This VT was mapped to the anteroseptal left ventricle
toward the base as shown by Carto mapping (top left) and ﬂuoroscopy in posteroanterior projection (top right). This episode of VT was terminated within 2 s after radiofrequency
ablation. Please note pre-systolic and diastolic potentials at successful ablation site in Carto map display. Another successful ablation site was located at the anteroseptal left ven-
tricle toward the apex. Surface lead I and arterial blood pressure are shown at bottom.
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CS lactate level (0.73 ± 0.22 vs 0.65 ± 0.21 mmol/L). Fig. 3(B)
shows the lactate level from the femoral artery under CPB support
in another patient with severe ischemic dilated cardiomyopathy
(LVEF of 15% and left ventricular end-diastolic dimension of
85 mm). The lactate level remained stable over a 90 min VT episode
in this patient except a transient increase at termination of VT by ab-
lation, when transient hypotension occurred following adjustment of
vasopressor doses. All patients with CPB or Impella support could be
weaned off without difﬁculties after MCS was withdrawn. None of
our patients had signiﬁcant postoperative heart failure exacerbation
that required hospitalization longer than anticipated prior to the
procedure.
3.5. Renal function
Overall, there was no signiﬁcant change in creatinine (102 ± 19 vs
102 ± 37 μmol/L, p = 0.958), blood urea nitrogen (7.5 ± 3.9 vs 6.4 ±
3.9 mmol/L, p = 0.062), or GFR (67 ± 15 vs 71 ± 18 mL/min/1.7 m2,
p = 0.135) on the following day after procedure compared to baseline
values before ablation procedure (Table 3). In only one patient with
bleeding and inadequate hemodynamic support with an Impella device,
his post-procedure creatinine was increased from 122 μmol/L at baseline
before ablation to 223 μmol/L, blood urea nitrogen was increased
from 8.9 mmol/L to 12.1 mmol/L, and GFR was decreased from 50 to
25 mL/min/1.7 m2. His renal function recovered gradually toward base-
line over a 5-week period.
3.6. Cerebral tissue regional oxygen saturation (rSO2) monitoring
None of our patients had clinically evident postoperative cognitive
decline. Fig. 4 shows cerebral rSO2 in one patient under CPB support
for unstable VT ablation. It was considered critical if rSO2 fell by 25%
(at approximately 40% in this patient as indicated by the red line in
the top graph). Cerebral rSO2 was initially 53%–59%; [24] and stable
between 40% and 50% (bottom graph) thereafter except occasional
drop with transient hypotension. A total of 7 VTs with different VT
morphology and/or cycle length were induced and all of these VTs
were terminated by radiofrequency ablation. This patient tolerated
the procedure well while on CPB for 116 min and in VT for 55 min
in total.3.7. Follow-up data
In the month immediately prior to VT ablation, there were a medi-
an of 6 (range 3–1376) episodes of VT that required ICD therapies
(shocks and antitachycardia pacing) among the remaining patients
who underwent ablation. In the month immediately post-ablation,
the number of VT episodes was signiﬁcantly (p = 0.001) reduced to
a median of 0 (range 0–1784). Over a one-month follow-up, ten of
these patients had no VT recurrence. VT episode frequency was
decreased after ablation in all patients except one. Despite a large
number of antitachycardia pacing attempts (n = 1784) in this
patient, the frequency of his fast VT (approximately 170–250 bpm)
was signiﬁcantly reduced (with 2 shocks over a 3-month follow-up
compared with 10 shocks in the month before ablation).
Clinical success (N75% reduction of VT episodes) over the ﬁrst
month was achieved in 13 of the 16 patients (81%). In the 3 patients
who did not achieve clinical success, one had slow VT, which was suc-
cessfully eliminated by repeat ablation procedure in this patient with
CF-LVAD. Another patient had amiodarone-induced hyperthyroid-
ism; and his VT was controlled without further recurrence after his
hyperthyroidism was improved. The third patient had progressive
heart failure and died one month after ablation procedure. Note that
this patient had only slow VT (at approximately 110 bpm) that
could be terminated by antitachycardia pacing early after ablation;
and ICD shocks only occurred prior to his death.
Over 3 months post-ablation, the number of VT episodes was sub-
stantially (p = 0.012) reduced to 0.2 (median, range 0–955) epi-
sodes per month. Eight of these patients had no VT recurrence at a
3-month follow-up. The median recurrent time after ablation was
55 days (ranging from 1 to N90 days). Clinical success was achieved
in 73% of the patients over the 3-month follow-up.
4. Discussion
4.1. Main ﬁnding
Our study demonstrated that hemodynamically unstable VT could be
stabilized with different MCS, permitting adequate activation mapping
for catheter ablation with reasonable clinical success and without
evidence of signiﬁcant ischemic injury to the vital organs, such as the
brain, heart, and kidneys in the majority of patients. There was minimal
Fig. 3. Arterial and coronary sinus (CS) lactate level during ablation of ventricular tachycardia (VT) with peripheral cardiopulmonary bypass (CPB) support. (A) It is noted that both
arterial and CS lactate level increased during transient hypotension. While mean arterial pressure (MAP) was maintained above 60 mmHg (79 mmHg in this patient), lactate level
stayed in the normal range. It appears that CS lactate level parallels well with arterial lactate level with correlation coefﬁcient of 0.89, suggesting that arterial lactate level can be
used to monitor cardiac lactate production as well as systematic production. (B) Arterial lactate remained essentially stable over a 90 min VT period for mapping and ablation. See
text for a detailed discussion. Proc = procedure.
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maintained above 60 mmHg in addition to other routine monitoring
techniques. However, Impella system (at a ﬂow rate of up to 2.5 L/min)
may not provide sufﬁcient support during unstable VT in some patients.
Finally, our data showed that the CS lactate level closely correlated with
systemic arterial lactate level.
4.2. Previous studies
Published data on catheter ablation of unstable VT under hemody-
namic support are scarce. Abuissa et al. [15] initially reported in 2010
their experience on successful catheter ablation under Impella support
in 3 patients with unstable VT. Miller et al. [16,25] reported their initial
experience on catheter ablation of hemodynamically unstable VT using
Impella. They found a more favorable hemodynamic proﬁle compared
with pharmacological agents alone or non-Impella groups. However,
our patients had signiﬁcantly worse left ventricular systolic function
(LVEF 20 ± 9% vs. 31 ± 16% in their patients), yielding slightly differ-
ent observation. Catheter ablation of unstable VT has also been reported
using other types of MCS such as TandemHeart [13,17].
It seems that peripheral CPB using a cut-down approach may be
the most effective approach for this procedure with excellent safetyproﬁle based on our preliminary data. It has been reported that CPB
with ﬂows between 2 and 3 L/min might be sufﬁcient to achieving
hemodynamic stabilization in selected patients with unstable VT
[14], similar to Impella 2.5. However, we found that CPB with full sup-
port (4 L/min) was needed in most of our sicker patients.
4.3. Patient monitoring
One of the most important concerns for ablation of unstable VT
using MCS is hypoperfusion to the vital organs. The principal intra-
procedural monitoring in this study is to keep MAP N60 mmHg during
MCS in addition to other routine monitoring [19]. Per our monitoring
protocol, none of our patients developed signiﬁcant ischemic dam-
age to any vital organ post ablation procedure unless profound hypo-
tension developed for prolonged periods. Our data that a MAP
of N60 mmHg during VT on MCS was rarely associated with a low
rSO2 suggests the importance in maintaining a MAP of N60 mmHg.
Comparable to the study by Miller et al. [16], the time in VT in our
study was 78 ± 36 min in the Impella and CPB groups with mean
time under hemodynamic support of 185 ± 86 min. No patients ex-
cept one with Impella required premature termination of sustained
VT due to hemodynamic instability in our study. Further, consistent
Fig. 4. Cerebral tissue regional oxygen saturation (rSO2) in a patient under CPB support for unstable VT ablation. A sample of one-hour cerebral rSO2 display is shown at the top.
Cerebral rSO2 was approximately between 40% and 50% (bottom graph) during electrophysiologic preparation. At approximately 12:00 pm, fast VT at 182 bpmwith systolic arterial
pressure down to 40 mmHg was induced and pace-terminated after approximately 25 s. After establishing CPB, VT was induced again targeted for mapping and ablation. In total,
this patient was on CPB for 116 min and in VT for 55 min.
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patients with CF-LVAD could also be safely and successfully ablated
without apparent complications.4.4. Study limitations
This study reports our preliminary experience on catheter ablation
of hemodynamically unstable VT utilizing MCS. There are several im-
portant limitations despite thatwe collected data carefully and prospec-
tively in each patient. (1) The study used a retrospective designwithout
randomization andwas limited to a relatively small number of patients.
Some data (such as lactate measurements and rSO2 monitoring) were
only performed in selected patients rather than the whole cohort. (2)
Such single center and single ablation operator experience with the as-
sistance of a multidisciplinary team may not readily be generalized
without further studies. (3) It is not totally appropriate to use the
CF-LVAD group as a control group in this study because they all had
end-stage cardiomyopathy and more severe heart failure under persis-
tent CF-LVAD support. (4) Such a complex and challenging procedure
involving an experienced multidisciplinary team will further limit its
routine use in daily practice. At last, the relatively high incidence
of Impella implantation-related groin vascular complications in this
cohort might also be a reﬂection of the learning curve in utilization of
Perclose devices in this patient population.4.5. Future perspectives
Although patients with VT frequently have left ventricular dysfunc-
tion, their left ventricular dysfunction is often not severe enough for
heart transplantation but may be sufﬁcient to generate hemodynami-
cally unstable VT. Without successful control of refractory VT in these
patients with medications or ablation, heart transplantation [28–30]
or implantation of long-term MCS devices, including total artiﬁcial
heart [30–32], may have to be considered. Whether catheter ablation
with the aid of temporary MCS provides a promising treatment option
to avoid or postpone the need in lieu of permanent MCS or heart trans-
plantation in such patients warrants further investigation.
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